Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial

• Comments Off on Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial
• Feb, 21, 2023
• Eddie Phanichkul
• Press Article

San Diego, February 21, 2023 (GLOBE NEWSWIRE) – Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease biomarkers in the eye, today announced initiation of enrollment of patients with cerebral amyloid angiopathy (CAA), an age-associated disease in which a protein called amyloid beta (Aβ) builds up […]